Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2012

View Archived Issues

Shionogi reports milestones of second quarter of fiscal 2012

Nonviral gene therapy for heart failure presented at AHA meeting

Kancera reports preclinical data for pancreatic cancer compounds

Phase III results reported for Ruconest in acute hereditary angioedema

Senesco Technologies expands study of SNS01-T

Auxilium and Pfizer to terminate European agreement for Xiapex

Auxilium seeks approval of new indication for Xiaflex in the U.S.

Clinical benefit of GLPG-0634 in rheumatoid arthritis confirmed in phase IIa trial

FDA grants fast track status for etirinotecan pegol in metastatic breast cancer

Albireo obtains FDA orphan drug designation for A-4250 in liver diseases

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Signifor recommended by FDA advisory committee for Cushing's disease

T-3256336 proven to be a highly effective inhibitor of tumor growth in vivo

IMA-901 receives FDA orphan designation, phase III study completes enrollment

Cornerstone acquires U.S. rights to Chiesi's Bethkis for cystic fibrosis

Merck & Co. presents novel BACE inhibitors

Laboratoire Biodim discloses new agents for HIV infection

Ironwood Pharmaceuticals submits IND for antianxiety drug candidate

Sloan-Kettering Institute for Cancer Research patents new HSP 90 inhibitors

Nektar Therapeutics synthesizes promising thymidylate synthase inhibitor

FDA accepts to review NDA for suvorexant in insomnia

Scientists at Vertex Pharmaceuticals patent new protein kinase inhibitors

Merck & Co. prepares novel agents for diabetes and obesity

Pfizer divulges new lpxC inhibitors for bacterial infections

Cryopraxis and CellPraxis plan phase III trial of cell therapy for refractory angina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...